47 related articles for article (PubMed ID: 18507097)
1. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.
Sheng XL; Zhang H
World J Gastroenterol; 2007 Nov; 13(44):5944-50. PubMed ID: 17990361
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.
Wang XH; Qin Y; Hu MH; Xie Y
Cancer Immunol Immunother; 2005 Oct; 54(10):971-80. PubMed ID: 15965645
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma.
Ren J; Jia J; Zhang H; Zhang L; Ma B; Jiang H; Di L; Song G; Yu J
Cancer Sci; 2008 Jul; 99(7):1420-6. PubMed ID: 18422751
[TBL] [Abstract][Full Text] [Related]
4. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
5. IL-12 improves the anti-HCC efficacy of dendritic cells loaded with exosomes from overexpressing Rab27a tumor cells.
Li J; Lin W; Huang T; Chen M; Lin Q
Exp Cell Res; 2024 Jun; 439(1):114073. PubMed ID: 38704079
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.
Iwashita Y; Tahara K; Goto S; Sasaki A; Kai S; Seike M; Chen CL; Kawano K; Kitano S
Cancer Immunol Immunother; 2003 Mar; 52(3):155-61. PubMed ID: 12649744
[TBL] [Abstract][Full Text] [Related]
7. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
8. In vitro antitumor immune response induced by fusion of dendritic cells and colon cancer cells.
Xu F; Ye YJ; Wang S
World J Gastroenterol; 2004 Apr; 10(8):1162-6. PubMed ID: 15069718
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-glioma fusion activates T lymphocytes by elevating cytotoxic efficiency as an antitumor vaccine.
Tian F; Dou C; Qi S; Chen B; Zhao L; Wang X
Cent Eur J Immunol; 2014; 39(3):265-70. PubMed ID: 26155134
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy of combined versus single immune cell adaptive therapy targeting colorectal cancer.
Che DN; Lee N; Lee HJ; Kim YW; Battulga S; Lee HN; Ham WK; Lee H; Lee MY; Kim D; Kang H; Yun S; Park J; Won DD; Lee JK
Ann Coloproctol; 2024 Apr; 40(2):121-135. PubMed ID: 38712438
[TBL] [Abstract][Full Text] [Related]
11. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
13. [Dendritic cell-based immunotherapy for hepatocellular carcinoma].
Nakamoto Y; Kaneko S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):413-6. PubMed ID: 20332677
[TBL] [Abstract][Full Text] [Related]
14. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
15. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
Gao J; Chen M; Peng ML; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
